Open Access

ARTICLE

Low-risk prostate cancer patient: active treatment

Judd W. Moul¹, Fred Saad²

1 Division of Urological Surgery, Duke University Medical Center, Durham, NC, USA
2 Department of Surgery (Urology), University of Montreal, CHUM, Montreal, Quebec, Canada
Address correspondence to Dr. Judd Moul, Division of Urologic Surgery, DUMC 3707-Room 1573 Duke South, Durham, NC 27710 USA

Canadian Journal of Urology 2005, 12(Suppl.3), 25-27.

Abstract

We currently lack a prospective, randomized, multicenter trial, to reassure low-risk prostate cancer patients, especially younger ones, that watchful waiting is a legitimate treatment. To better manage these patients, we need to: first, confirm that the patient has low-risk prostate cancer; second, adapt the treatment to the risk (i.e., if therapy is chosen over watchful waiting, it should be monotherapy not multiple therapy); third, be aware of age migration; fourth, know that radical prostatectomy and radiation were shown to be very effective for these patients at 10-year follow-up; and lastly, make an effort to better define watchful waiting and embrace it more, to avoid overtreatment.

---

Keywords

---